Emulating the CLEAR Trial: A Target Trial Using Electronic Health Records to Assess the Efficacy and Tolerability of Clozapine vs other antipsychotics in Young People with Treatment-Resistant Psychosis (CLEAR-EHR)
Clozapine is the only recommended treatment for treatment-resistant schizophrenia (TRS) but data on young people are still scarse and contradicting. The CLEAR-EHR study is a target trial that aims to estimate the effectiveness of clozapine versus standard antipsychotics (TAU) on clinical outcomes in young people (aged 12–24) with TRS.